Health Observance

World Tuberculosis Day

ASBMB Today Staff
By ASBMB Today Staff
March 23, 2018

On March 24, 1882, microbiologist Robert Koch announced to colleagues at the Physiological Society of Berlin that he had found the bacterium that causes tuberculosis. Thanks to his work, and the work of many other researchers, the disease is now both preventable and curable. However, millions of people are still infected each year worldwide.

Along with the Centers for Disease Control and Prevention and other organizations around the world, the ASBMB is observing Tuberculosis Day 2018 by sharing research news from scientists expanding our understanding of Mycobacterium tuberculosis and a variety of perspectives on how the pathogen continues to affect our world.

health-observance-tb-primary.pngMolecular & Cellular Proteomics

Improving TB vaccination
Mycobacterium vaccae, a species related to M. tuberculosis, is an immunogen of increasing interest as a possible vaccine. Scientists at the Chinese Academy of Medical Sciences used a proteomic analysis to pinpoint several immunogenic proteins in M. vaccae and reported their findings here.

A drug discovery resource
The first serine/threonine protein kinase interaction map for M tuberculosis was reported in MCP in June. The database, a resource for drug development, can be accessed here.

Bacterial immune evasion
In this study, researchers from Shanghai Jiao Tong University systematically assayed interacting proteins from M. tuberculosis and human proteomes, discovering a novel effector that binds to and suppresses a human ribosomal protein. Read more on their findings here.

Journal of Biological Chemistry

A prodrug-activating enzyme
TP053 is a promising anti-tuberculosis drug with potential to kill both replicating and nonreplicating bacteria. TP053 is a prodrug that must be activated by a redox enzyme from M. tuberculosis called DsbA. Researchers from across Europe characterized the role of DsbA in protecting the bacteria from oxidative stress. Read the article here

Bacterial enzymology
The M. tuberculosis cytochrome P450 enzyme CYP121 is crucial for viability.  But unlike the average cytochrome P450, CYP121 catalyzes a crosslink between carbon atoms. Researchers at the University of Texas at San Antonio used enzyme kinetics to characterize the reaction and propose a mechanism in this paper in JBC

Hypoxic survival mechanisms
M. tuberculosis can survive in hypoxic microenvironments within the host alveolar macrophage by stealing and metabolizing host lipids. In a JBC article, scientists from India’s National Institute of Immunology identified an enzyme with lipase and protease activities key to hydrolyzing host lipids. Read the article here.

A function for a bacterial enzyme
After M. tuberculosis infects the host macrophage, it rapidly increases expression of the gene Rv2633, whose function was unknown. A research team at the University of Central Florida reported that the gene product is a catalase enzyme that protects the bacterium from oxidative stress during the host immune response in this paper in JBC.

Dual roles for a protein kinase
Mycobacterium tuberculosis virulence factor protein kinase G, or PKnG, prevents fusion of the host phagosome and lysosome, protecting the bacteria within the macrophage. Scientists from India’s National Institute of Immunology and the Indian Institute of Technology found that PKnG is also critical for bacterial survival during latency-like conditions, affecting the level of various substrates involved in metabolism. Read their article here.

Crystallizing a drug target
Antigen 85, which is important for the synthesis of the M. tuberculosis mycomembrane, is a target for a new class of cyclipostin and cyclophostin analogs. In a recent JBC article, researchers at the Centre National de la Recherche Scientifique in France reported the crystal structure of a cyclopostin analog bound to antigen 85, both demonstrating how the drug in question works and suggesting future approaches for drug design. Read their article here.

Predicting when rifampicin will fail
The antibiotic rifampicin is a first-line therapy for TB. In a recent paper, scientists from the Council of Scientific and Industrial Research in India identified a xenobiotic nuclear receptor from patients with rifampicin-susceptible infections who were not responding to therapy; the receptor dulls rifampicin’s effects. The finding suggests that adding a receptor antagonist may make a more potent therapeutic cocktail. Read more here.

Targeting the latent stage
The ribonucleolytic enzyme MazF is a promising drug target for the latent stage of tuberculosis. Researchers from Seoul National University in Korea described the protein’s structure in a paper accessible here

Journal of Lipid Research

Improving diagnostics
Historically, diagnosis of tuberculosis has been challenging and subjective. In this article, scientists at the National University of Singapore used a phage display system to develop four antibodies specific for mycolic acid from the mycobacterial cell wall. While recent advances in nucleic acid diagnostics such as the GenXpert mean a lipid-based diagnostic is now less of a priority for tuberculosis, the approach could be used to develop diagnostic assays based on a variety of lipid biomarkers from different pathogens. Find out how the phage display system works here. 

ASBMB Today Staff
ASBMB Today Staff

This article was written by a member or members of the ASBMB Today staff.

Join the ASBMB Today mailing list

Sign up to get updates on articles, interviews and events.

Latest in Science

Science highlights or most popular articles

Life's little oscillations
News

Life's little oscillations

April 05, 2020

Concentrations of molecules rise and fall, genes switch on and off, and circadian clocks keep time. These biochemical fluctuations are crucial for myriad biological needs, and cells couldn't function without them.

A small trial finds that hydroxychloroquine is not effective for treating coronavirus
News

A small trial finds that hydroxychloroquine is not effective for treating coronavirus

April 05, 2020

Despite the recent approval of this drug for use against COVID-19, questions remain as to the efficacy of this treatment.

Team Cryo ices Mass Spec’s hopes in JBC Methods Madness tourney
Journal News

Team Cryo ices Mass Spec’s hopes in JBC Methods Madness tourney

April 03, 2020

In the inaugural JBC Methods Madness Tournament, cryo­–EM/ET gave structural biologists around the world something to cheer about, beating mass spectrometry 51% to 49% —​ a margin thinner than shaved ice. 

A small army of researchers races to build a coronavirus interactome
News

A small army of researchers races to build a coronavirus interactome

April 01, 2020

Scientists at eight institutions in the U.S. and Europe have used a protein interaction map to identify 69 drugs that might work against SARS-CoV-2, the virus that causes COVID-19.

Parkinson's  Awareness Month
Health Observance

Parkinson's Awareness Month

April 01, 2020

It is the second-most common progressive neurodegenerative disease, occurring in 1% of people over the age of 60 and in 5% of people over 85.

Multiomics meets antimalarials
Journal News

Multiomics meets antimalarials

March 31, 2020

Researchers in Australia use an innovative multiomics approach to analyze a new drug against malaria parasites.